NS

Nihal Sinha

Partner, F-Prime Capital

London, England

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $10,000,000.00

  • Target Investment:

    $5,000,000.00

Skills

Venture Capital
Healthcare
Life Sciences
Science
Neuroscience
Strategy
Clinical Research
Lifesciences
Management Consulting
Medicine
Entrepreneurship
Biotechnology
Start-ups
Business Development
Leadership
Project Management

Education

Investments

T-Therapeutics

Series A

Total Funding: $60M

Elucidata

Series A

Total Funding: $23M

RIGImmune

Seed

Total Funding:

CHARM Therapeutics

Series A

Total Funding: $50M

Work Experience

F-Prime Capital

2014

  • Partner

    2014

    F-Prime Capital is a global venture capital firm investing in healthcare and technology companies.

T-Therapeutics Ltd

2023

  • Board Director

    2023

CHARM Therapeutics

2021

  • Board Director, Founding Investor

    2021

Ensoma

2023

  • Board Director

    2023

AviadoBio

2020

  • Board Director

    2020

Orchard Therapeutics

2016 - 2019

  • Founding Team

    2016 - 2019

    Founding Team. Interim Medical Director.

Fidelity Biosciences

2013 - 2014

  • Analyst

    2013 - 2014

    Venture capital analyst in life sciences and healthcare

The Boston Consulting Group

2012 - 2013

  • Management Consultant

    2012 - 2013

OXFORD UNIVERSITY HOSPITALS NHS TRUST

2010 - 2012

  • Academic Clinical Fellow

    2010 - 2012

University of Cambridge

2005 - 2012

  • Neuroscience Supervisor

    2005 - 2012